VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Update

VolitionRX Limited (NYSEAMERICAN:VNRX) saw a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 538,529 shares, a growth of 101.2% from the July 15th total of 267,687 shares. Currently, 6.7% of the shares of the company are sold short. Based on an average trading volume of 308,439 shares, the days-to-cover ratio is currently 1.7 days.

VolitionRX Stock Performance

NYSEAMERICAN VNRX traded down $0.09 during trading on Friday, hitting $0.54. 952,532 shares of the company’s stock traded hands, compared to its average volume of 939,791. The stock has a market capitalization of $4.64 million, a price-to-earnings ratio of -0.14 and a beta of 1.16. VolitionRX has a 12-month low of $0.53 and a 12-month high of $15.10. The business has a 50 day moving average of $1.13 and a 200-day moving average of $2.74.

VolitionRX (NYSEAMERICAN:VNRX) last posted its earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.41 million. On average, analysts expect that VolitionRX will post -2.36 EPS for the current year.

Analyst Upgrades and Downgrades

VNRX has been the topic of a number of recent analyst reports. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. Benchmark restated a “hold” rating on shares of VolitionRX in a research note on Tuesday, June 2nd. Maxim Group reaffirmed a “buy” rating and set a $4.00 target price on shares of VolitionRX in a research report on Thursday, June 18th. Finally, Citigroup cut VolitionRX to a “hold” rating in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of VNRX. Virtu Financial LLC lifted its position in shares of VolitionRX by 166.6% during the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after acquiring an additional 67,848 shares in the last quarter. Armistice Capital LLC boosted its holdings in shares of VolitionRX by 10.4% in the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after acquiring an additional 887,351 shares during the period. Geode Capital Management LLC boosted its holdings in shares of VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after acquiring an additional 85,816 shares during the period. Citadel Advisors LLC grew its position in shares of VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after purchasing an additional 135,775 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in shares of VolitionRX during the 2nd quarter valued at $52,000. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.